FibroGen, Inc (FGEN) Director Sells $1,298,000.00 in Stock
FibroGen, Inc (NASDAQ:FGEN) Director Rory B. Riggs sold 25,000 shares of FibroGen stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $51.92, for a total value of $1,298,000.00. Following the transaction, the director now owns 435,200 shares in the company, valued at approximately $22,595,584. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of FibroGen, Inc (NASDAQ:FGEN) traded up 0.58% during mid-day trading on Friday, reaching $52.40. 1,462,946 shares of the company traded hands. The stock’s market capitalization is $3.73 billion. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $52.70. The company’s 50 day moving average is $42.78 and its 200 day moving average is $31.87.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. On average, equities analysts forecast that FibroGen, Inc will post ($1.80) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “FibroGen, Inc (FGEN) Director Sells $1,298,000.00 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/fibrogen-inc-fgen-director-sells-1298000-00-in-stock.html.
A number of large investors have recently modified their holdings of FGEN. BlackRock Inc. boosted its stake in FibroGen by 29,724.1% in the 1st quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares during the last quarter. FMR LLC boosted its stake in FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares during the last quarter. EcoR1 Capital LLC boosted its stake in FibroGen by 3,674.1% in the 2nd quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock worth $51,210,000 after buying an additional 1,543,448 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in FibroGen in the 2nd quarter worth about $45,633,000. Finally, Vanguard Group Inc. boosted its stake in FibroGen by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after buying an additional 761,421 shares during the last quarter. 47.49% of the stock is currently owned by hedge funds and other institutional investors.
FGEN has been the topic of several research analyst reports. Jefferies Group LLC initiated coverage on shares of FibroGen in a report on Monday, July 10th. They issued a “buy” rating and a $50.00 price objective on the stock. Leerink Swann restated an “outperform” rating and issued a $82.00 price objective (up from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. William Blair restated an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Citigroup Inc. boosted their price objective on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a report on Tuesday, August 8th. Finally, BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $60.17.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.